Connection

Jacobo Mintzer to Humans

Back to Details
This is a "connection" page, showing publications Jacobo Mintzer has written about Humans.
Jacobo Mintzer
Connection Strength
0.735
Humans
  1. Dementia in the incarcerated population: a retrospective study using the South Carolina Alzheimer's disease registry, USA. Int J Prison Health. 2023 02 27; ahead-of-print(ahead-of-print).
    View in: PubMed
    Score: 0.033
  2. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
    View in: PubMed
    Score: 0.031
  3. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. Am J Geriatr Psychiatry. 2021 01; 29(1):81-89.
    View in: PubMed
    Score: 0.028
  4. A retrospective, population-based cohort study of driving under the influence, Alzheimer's disease diagnosis, and survival. Int Psychogeriatr. 2019 04; 31(4):571-577.
    View in: PubMed
    Score: 0.025
  5. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr. 2014 Feb; 26(2):239-46.
    View in: PubMed
    Score: 0.018
  6. The state of psychogeriatrics in different regions of the world: challenges and opportunities. Int Psychogeriatr. 2013 Oct; 25(10):1563-9.
    View in: PubMed
    Score: 0.017
  7. Depression in Alzheimer's disease: consequence or contributing factor? Expert Rev Neurother. 2011 Nov; 11(11):1501-3.
    View in: PubMed
    Score: 0.015
  8. Establishment of a predominantly African-American cohort for the study of Alzheimer's disease: the South Carolina Alzheimer's disease clinical core. Dement Geriatr Cogn Disord. 2009; 27(4):329-36.
    View in: PubMed
    Score: 0.013
  9. Using risperidone for Alzheimer's dementia-associated psychosis. Expert Opin Pharmacother. 2008 Oct; 9(14):2537-43.
    View in: PubMed
    Score: 0.012
  10. Notably higher rates of vascular risk factors and dementia among African Americans in South Carolina: opportunities for public health intervention. J S C Med Assoc. 2008 Oct; 104(7):219-22.
    View in: PubMed
    Score: 0.012
  11. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. Clin Drug Investig. 2008; 28(5):291-303.
    View in: PubMed
    Score: 0.012
  12. The many faces of psychosis in the elderly. Curr Opin Psychiatry. 2007 Nov; 20(6):551-8.
    View in: PubMed
    Score: 0.012
  13. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov; 15(11):918-31.
    View in: PubMed
    Score: 0.012
  14. Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. Int Psychogeriatr. 2007 Jun; 19(3):539-58.
    View in: PubMed
    Score: 0.011
  15. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91.
    View in: PubMed
    Score: 0.010
  16. Introduction: the clinical impact of agitation in various psychiatric disorders: management consensus and controversies. J Clin Psychiatry. 2006; 67 Suppl 10:3-5.
    View in: PubMed
    Score: 0.010
  17. The growing, ethnically diverse aging population: is our field advancing with it? Am J Geriatr Psychiatry. 2005 Jul; 13(7):541-4.
    View in: PubMed
    Score: 0.010
  18. Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord. 2005 Jan-Mar; 19(1):37-40.
    View in: PubMed
    Score: 0.010
  19. A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Curr Med Res Opin. 2004 Sep; 20(9):1483-91.
    View in: PubMed
    Score: 0.009
  20. Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets. 2004 Aug; 5(6):517-28.
    View in: PubMed
    Score: 0.009
  21. Assessing current practice in Alzheimer's disease. CNS Spectr. 2004 Jul; 9(7 Suppl 5):5.
    View in: PubMed
    Score: 0.009
  22. What are the challenges faced by psychiatrists in the management of Alzheimer's disease? CNS Spectr. 2004 Jul; 9(7 Suppl 5):13-5.
    View in: PubMed
    Score: 0.009
  23. Elderly veterans with combat-related posttraumatic stress disorder in specialty care. J Nerv Ment Dis. 2004 Jan; 192(1):75-9.
    View in: PubMed
    Score: 0.009
  24. Psychosis in elderly patients: classification and pharmacotherapy. J Geriatr Psychiatry Neurol. 2003 Dec; 16(4):199-206.
    View in: PubMed
    Score: 0.009
  25. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry. 2003 Apr; 18(4):292-7.
    View in: PubMed
    Score: 0.008
  26. The search for better noncholinergic treatment options for Alzheimer's disease. J Clin Psychiatry. 2003; 64 Suppl 9:18-22.
    View in: PubMed
    Score: 0.008
  27. Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. Psychopharmacol Bull. 2003; 37(4):116-32.
    View in: PubMed
    Score: 0.008
  28. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry. 2001 Dec; 16 Suppl 1:S71-7.
    View in: PubMed
    Score: 0.008
  29. Diagnostic criteria for apathy in neurocognitive disorders. Alzheimers Dement. 2021 12; 17(12):1892-1904.
    View in: PubMed
    Score: 0.007
  30. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. J Intern Med. 2021 08; 290(2):310-334.
    View in: PubMed
    Score: 0.007
  31. Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial. J Neurotrauma. 2021 07 15; 38(14):1943-1952.
    View in: PubMed
    Score: 0.007
  32. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. Am J Geriatr Psychiatry. 2021 01; 29(1):51-62.
    View in: PubMed
    Score: 0.007
  33. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019 11; 15(11):1427-1436.
    View in: PubMed
    Score: 0.007
  34. Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation. Biol Psychiatry. 1998 Nov 01; 44(9):918-21.
    View in: PubMed
    Score: 0.006
  35. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2018 11; 33(7):450-457.
    View in: PubMed
    Score: 0.006
  36. Treatment of agitation in patients with dementia. Clin Geriatr Med. 1998 Feb; 14(1):147-75.
    View in: PubMed
    Score: 0.006
  37. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.
    View in: PubMed
    Score: 0.006
  38. Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2018; 5(2):98-102.
    View in: PubMed
    Score: 0.006
  39. Psychometric Properties of Apathy Scales in Dementia: A Systematic Review. J Alzheimers Dis. 2018; 66(3):1065-1082.
    View in: PubMed
    Score: 0.006
  40. Identifying persons with dementia by use of a caregiver telephone interview. Am J Geriatr Psychiatry. 1998; 6(2):176-9.
    View in: PubMed
    Score: 0.006
  41. Effectiveness of a continuum of care using brief and partial hospitalization for agitated dementia patients. Psychiatr Serv. 1997 Nov; 48(11):1435-9.
    View in: PubMed
    Score: 0.006
  42. Fluoroquinolone inhibition of clozapine metabolism. Am J Psychiatry. 1997 Jun; 154(6):881.
    View in: PubMed
    Score: 0.006
  43. Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations. Am J Psychiatry. 2017 04 01; 174(4):362-369.
    View in: PubMed
    Score: 0.005
  44. Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of?Alzheimer's Disease. J Alzheimers Dis. 2016 08 10; 54(1):373-81.
    View in: PubMed
    Score: 0.005
  45. Zolpidem for the treatment of agitation in elderly demented patients. J Clin Psychiatry. 1996 Aug; 57(8):372-3.
    View in: PubMed
    Score: 0.005
  46. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016 09; 82(3):784-92.
    View in: PubMed
    Score: 0.005
  47. Alzheimer's disease and managed care: challenges and strategies. J S C Med Assoc. 1996 Jun; 92(6):255-60.
    View in: PubMed
    Score: 0.005
  48. Principal components analysis of agitation outcomes in Alzheimer's disease. J Psychiatr Res. 2016 08; 79:4-7.
    View in: PubMed
    Score: 0.005
  49. Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. Am J Psychiatry. 2016 May 01; 173(5):473-80.
    View in: PubMed
    Score: 0.005
  50. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72.
    View in: PubMed
    Score: 0.005
  51. Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. J Clin Psychiatry. 1996; 57 Suppl 7:55-63; discussion 73-5.
    View in: PubMed
    Score: 0.005
  52. Cross-cultural perspectives: agitation in demented patients in the United States. Int Psychogeriatr. 1996; 8 Suppl 3:487-90; discussion 491-2.
    View in: PubMed
    Score: 0.005
  53. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. J Psychiatr Res. 2016 Mar; 74:17-21.
    View in: PubMed
    Score: 0.005
  54. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109.
    View in: PubMed
    Score: 0.005
  55. The neural correlates of anomia in the conversion from mild cognitive impairment to Alzheimer's disease. Neuroradiology. 2016 Jan; 58(1):59-67.
    View in: PubMed
    Score: 0.005
  56. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91.
    View in: PubMed
    Score: 0.005
  57. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015 Sep 22-29; 314(12):1242-54.
    View in: PubMed
    Score: 0.005
  58. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015 Dec; 27(12):2059-67.
    View in: PubMed
    Score: 0.005
  59. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64.
    View in: PubMed
    Score: 0.005
  60. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33.
    View in: PubMed
    Score: 0.005
  61. SIADH associated with fluoxetine and sertraline therapy. Am J Psychiatry. 1995 May; 152(5):809-10.
    View in: PubMed
    Score: 0.005
  62. New approaches in the treatment of Alzheimer's disease. J S C Med Assoc. 1994 Nov; 90(11):553-9.
    View in: PubMed
    Score: 0.005
  63. The state of psychogeriatrics in Europe: challenges and opportunities in six European countries. Int Psychogeriatr. 2015 Aug; 27(8):1243-6.
    View in: PubMed
    Score: 0.005
  64. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015 Jan; 27(1):7-17.
    View in: PubMed
    Score: 0.005
  65. Induction of salivary nerve growth factor by Yogic breathing: a randomized controlled trial. Int Psychogeriatr. 2015 Jan; 27(1):168-70.
    View in: PubMed
    Score: 0.005
  66. A new approach for the management of acute psychiatric disorders in elderly demented patients. J S C Med Assoc. 1994 Aug; 90(8):373-6.
    View in: PubMed
    Score: 0.005
  67. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014; 9(6):e98426.
    View in: PubMed
    Score: 0.005
  68. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19; 311(7):682-91.
    View in: PubMed
    Score: 0.004
  69. Spinal cord injury: how can we improve the classification and quantification of its severity and prognosis? J Neurotrauma. 2014 Feb 01; 31(3):215-27.
    View in: PubMed
    Score: 0.004
  70. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24.
    View in: PubMed
    Score: 0.004
  71. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 01; 311(1):33-44.
    View in: PubMed
    Score: 0.004
  72. Behavioral Intensive Care Unit (BICU): a new concept in the management of acute agitated behavior in elderly demented patients. Gerontologist. 1993 Dec; 33(6):801-6.
    View in: PubMed
    Score: 0.004
  73. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013 Aug; 74(8):810-6.
    View in: PubMed
    Score: 0.004
  74. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimers Dement. 2014 Jan; 10(1):36-44.
    View in: PubMed
    Score: 0.004
  75. Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). Am J Geriatr Psychiatry. 2013 Jun; 21(6):549-59.
    View in: PubMed
    Score: 0.004
  76. Attentional functioning in patients with posttraumatic stress disorder: a preliminary study. CNS Spectr. 2013 Apr; 18(2):90-4.
    View in: PubMed
    Score: 0.004
  77. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44.
    View in: PubMed
    Score: 0.004
  78. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012 Oct 18; 367(16):1497-507.
    View in: PubMed
    Score: 0.004
  79. Exploratory analysis of seven Alzheimer's disease genes: disease progression. Neurobiol Aging. 2013 Apr; 34(4):1310.e1-7.
    View in: PubMed
    Score: 0.004
  80. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2012 Sep; 27(6):421-32.
    View in: PubMed
    Score: 0.004
  81. Daughters caregiving for Hispanic and non-Hispanic Alzheimer patients: does ethnicity make a difference? Community Ment Health J. 1992 Aug; 28(4):293-303.
    View in: PubMed
    Score: 0.004
  82. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012 Apr; 20(4):362-73.
    View in: PubMed
    Score: 0.004
  83. Prevalence of depressive symptoms among white and African-American caregivers of demented patients. Am J Psychiatry. 1992 Apr; 149(4):575-6.
    View in: PubMed
    Score: 0.004
  84. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90.
    View in: PubMed
    Score: 0.004
  85. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012; 8(2):121-30.
    View in: PubMed
    Score: 0.004
  86. Sertraline for the treatment of depression in Alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8.
    View in: PubMed
    Score: 0.004
  87. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ? 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011 Jun; 26(6):573-83.
    View in: PubMed
    Score: 0.004
  88. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology. 2011 Mar; 258(3):843-52.
    View in: PubMed
    Score: 0.004
  89. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr; 18(4):332-40.
    View in: PubMed
    Score: 0.003
  90. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45.
    View in: PubMed
    Score: 0.003
  91. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008 Mar; 4(2):65-79.
    View in: PubMed
    Score: 0.003
  92. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008 Feb; 5(1):83-9.
    View in: PubMed
    Score: 0.003
  93. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May; 22(5):475-84.
    View in: PubMed
    Score: 0.003
  94. Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort. Arch Clin Neuropsychol. 2007 Mar; 22(3):405-14.
    View in: PubMed
    Score: 0.003
  95. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007 Feb; 4(1):81-93.
    View in: PubMed
    Score: 0.003
  96. Design of Depression in Alzheimer's Disease Study-2. Am J Geriatr Psychiatry. 2006 Nov; 14(11):920-30.
    View in: PubMed
    Score: 0.003
  97. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.
    View in: PubMed
    Score: 0.003
  98. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005 Nov; 13(11):942-9.
    View in: PubMed
    Score: 0.003
  99. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. Int J Geriatr Psychiatry. 2005 Feb; 20(2):119-27.
    View in: PubMed
    Score: 0.002
  100. Dementia with Lewy bodies. Lancet Neurol. 2004 Jan; 3(1):19-28.
    View in: PubMed
    Score: 0.002
  101. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004 Jan; 19(1):9-18.
    View in: PubMed
    Score: 0.002
  102. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66.
    View in: PubMed
    Score: 0.002
  103. Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study. Depress Anxiety. 2004; 19(4):249-56.
    View in: PubMed
    Score: 0.002
  104. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003 Nov; 160(11):2003-11.
    View in: PubMed
    Score: 0.002
  105. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
    View in: PubMed
    Score: 0.002
  106. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002 Apr; 26(4):494-504.
    View in: PubMed
    Score: 0.002
  107. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001 Nov; 71(5):589-95.
    View in: PubMed
    Score: 0.002
  108. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase. 2001; 7(2):105-10.
    View in: PubMed
    Score: 0.002
  109. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000 Sep; 93(9):457-62.
    View in: PubMed
    Score: 0.002
  110. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12; 52(6):1146-52.
    View in: PubMed
    Score: 0.002
  111. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb; 60(2):107-15.
    View in: PubMed
    Score: 0.002
  112. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry. 1995 May; 56(5):180-5.
    View in: PubMed
    Score: 0.001
  113. A comparative analysis of functional status among Spanish- and English-speaking patients with dementia. J Gerontol. 1992 Nov; 47(6):P389-94.
    View in: PubMed
    Score: 0.001
  114. The occurrence of different intrusive errors in patients with Alzheimer's disease, multiple cerebral infarctions, and major depression. Brain Cogn. 1991 May; 16(1):104-17.
    View in: PubMed
    Score: 0.001
  115. Acute desensitization of lymphocyte beta-adrenergic-stimulated adenylate cyclase in old age and Alzheimer's disease. Life Sci. 1984 Oct 22; 35(17):1795-802.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.